JP2001508068A - 胃腸系での活性物質の制御放出を用いた膨張性胃内貯留治療システム - Google Patents
胃腸系での活性物質の制御放出を用いた膨張性胃内貯留治療システムInfo
- Publication number
- JP2001508068A JP2001508068A JP53131998A JP53131998A JP2001508068A JP 2001508068 A JP2001508068 A JP 2001508068A JP 53131998 A JP53131998 A JP 53131998A JP 53131998 A JP53131998 A JP 53131998A JP 2001508068 A JP2001508068 A JP 2001508068A
- Authority
- JP
- Japan
- Prior art keywords
- active compound
- gastric juice
- multiparticulate
- formulation
- contact
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013270 controlled release Methods 0.000 title claims abstract description 9
- 210000005095 gastrointestinal system Anatomy 0.000 title claims abstract description 8
- 230000002496 gastric effect Effects 0.000 title description 11
- 230000014759 maintenance of location Effects 0.000 title description 6
- 239000013543 active substance Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 239000000203 mixture Substances 0.000 claims abstract description 58
- 238000009472 formulation Methods 0.000 claims abstract description 47
- 229920000642 polymer Polymers 0.000 claims abstract description 32
- 210000004051 gastric juice Anatomy 0.000 claims abstract description 31
- 230000003111 delayed effect Effects 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 18
- 239000011859 microparticle Substances 0.000 claims description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 9
- 239000001569 carbon dioxide Substances 0.000 claims description 9
- 210000000813 small intestine Anatomy 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 210000002784 stomach Anatomy 0.000 claims description 7
- 239000007903 gelatin capsule Substances 0.000 claims description 5
- 210000002429 large intestine Anatomy 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- 230000036528 appetite Effects 0.000 claims description 4
- 235000019789 appetite Nutrition 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 230000003628 erosive effect Effects 0.000 claims description 3
- 235000003642 hunger Nutrition 0.000 claims description 3
- 229920006254 polymer film Polymers 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 208000012895 Gastric disease Diseases 0.000 claims 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 1
- 238000004026 adhesive bonding Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 abstract description 8
- 239000007789 gas Substances 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 230000035699 permeability Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229920005597 polymer membrane Polymers 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000006224 matting agent Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.胃腸系において活性化合物を制御放出し、幽門通過を遅延させるためのデバ イスであって、胃液と接触すると膨張可能な成分を有し、前記成分は、胃液およ び活性化合物を透過可能なポリマーカバーに囲まれており、少なくとも一つの活 性化合物が活性化合物を胃液へ遅らせて放出する多微粒子製剤中に存在すること を特徴とするデバイス。 2.前記多微粒子製剤の個々の微粒子の少なくともいくつかは、活性化合物の前 記放出を制御するコーティングを有することを特徴とする請求項1に記載のデバ イス。 3.前記多微粒子製剤の個々の微粒子は、少なくともいくつかの、脂肪親和性で 、溶性が低い、または溶解速度が遅く、あるいは浸食の遅い物質内にマトリック ス形態で埋め込まれた活性化合物を含むことを特徴とする請求項1または2に記 載のデバイス。 4.活性化合物のいくつかは、多微粒子、迅速放出製剤に存在することを特徴と する請求項1から3のいずれかに記載のデバイス。 5.前記多微粒子製剤は、部分的にまたは完全に、ポリマーカバーに埋め込まれ ていることを特徴とする請求項1から4のいずれかに記載のデバイス。 6.これは、投与のために、例えば、固いゼラチンカプセルのような、胃液内で 急速に分解する追加のカバーに投入されることを特徴とする請求項1から5のい ずれかに記載のデバイス。 7.胃液と接触して気体を発生する、さらなる多微粒子製剤を含むことを特徴と する請求項1から6のいずれかに記載のデバイス。 8.前記さらなる多微粒子製剤は、炭酸水素塩を含み、かつ/または胃液と接触 して二酸化炭素を発生することを特徴とする請求項7に記載のデバイス。 9.前記さらなる多微粒子製剤の個々の微粒子の少なくともいくつかは、気体放 出を制御するコーティングを有することを特徴とする請求項1から8のいずれか に記載のデバイス。 10.前記さらなる多微粒子製剤の個々の微粒子の少なくともいくつかは、胃液 と接触して気体を発生し、脂肪親和性で、溶性が低い、または溶解速度が遅く、 あるいは浸食の遅い物質内にマトリックス形態で埋め込まれた物質を含むことを 特徴とする請求項1から9のいずれかに記載のデバイス。 11.胃液と接触して気体を発生する物質が、多微粒子迅速放出製剤中に、少な くとも部分的に存在することを特徴とする請求項1から10のいずれかに記載の デバイス。 12.前記ポリマーカバーは、水性液体中では膨張するが、40℃以下の温度で はおおむね不溶性である親水性ポリマーを用い、必要に応じて、さらに物質を用 いて、1つ以上の層から形成されることを特徴とする請求項1から11のいずれ かに記載のデバイス。 13.前記ポリマーカバーの構成または組成は、局部的に異なることを特徴とす る請求項1から12のいずれかに記載のデバイス。 14.前記ポリマーカバーは、少なくとも1つは膨張可能ないくつかの区画を形 成するように形成されることを特徴とする請求項1から13のいずれかに記載の デバイス。 15.胃の障害に対して効果的な少なくとも一つの活性化合物を含むことを特徴 とする請求項1から14のいずれかに記載のデバイス。 16.胃腸系の他の部分よりも、胃内または小腸の上部において、より迅速にお よび/またはより多く吸収される、少なくとも一つの活性化合物を含むことを特 徴とする請求項1から15のいずれかに記載のデバイス。 17.小腸および/または大腸の中間において比較的低い安定性を有する、ある いは、小腸および/または大腸の中間において発生する物質または微生物の影響 から、生物学的利用能の程度が低下することのある、少なくとも一つの活性化合 物を含むことを特徴とする請求項1から16のいずれかに記載のデバイス。 18.胃液と接触して、前記活性化合物の多微粒子製剤の組成および量によって 、少なくとも8時間これを放出することを特徴とする請求項1から17のいずれ かに記載のデバイス。 19.胃液と接触して、前記さらなる多微粒子製剤の組成および量によって、な らびに前記ポリマー膜の組成および構成によって、少なくとも8時間膨張するこ とを特徴とする請求項1から18のいずれかに記載のデバイス。 20.遅延させた幽門通過および含まれる活性化合物により、食欲および/また は空腹感の減退に適した薬剤の調製のための請求項1から19のいずれかに記載 のデバイスの使用。 21.請求項1から20のいずれかに記載のデバイスの調製のための多工程プロ セスであり、 1つのプロセス工程では、ポリマーカバー形成のための網状物質を調製し、網 状物質の2つの層が隣接または重なり合うように接着させ、 さらなるプロセス工程では、前記層と層の間を密着させることにより、前記多 微粒子製剤の進入のための分離した区画であるが、完全には密封されていない区 画を形成し、 さらなるプロセス工程では、前記多微粒子製剤を計量し各区画へ充填し、 さらなるプロセス工程では、前記区画を密封し、 さらなるプロセス工程では、前記個々のデバイスをスタンピングまたは切断す ることにより得、 さらなるプロセス工程では、前記デバイスを折りたたんだり、巻いたり、また は圧縮したりして、固いゼラチンカプセルに充填することを特徴とするプロセス 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19700915 | 1997-01-14 | ||
DE19700915.8 | 1997-01-14 | ||
PCT/EP1998/000099 WO1998031341A1 (de) | 1997-01-14 | 1998-01-09 | Expandierbares gastroretentives therapie-system mit kontrollierter wirkstofffreisetzung im gastrointestinaltrakt |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001508068A true JP2001508068A (ja) | 2001-06-19 |
JP3825811B2 JP3825811B2 (ja) | 2006-09-27 |
Family
ID=7817288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53131998A Expired - Fee Related JP3825811B2 (ja) | 1997-01-14 | 1998-01-09 | 胃腸系での活性物質の制御放出を用いた膨張性胃内貯留治療システム |
Country Status (20)
Country | Link |
---|---|
US (1) | US6290989B1 (ja) |
EP (1) | EP0961611B1 (ja) |
JP (1) | JP3825811B2 (ja) |
KR (1) | KR100503266B1 (ja) |
AT (1) | ATE214916T1 (ja) |
AU (1) | AU727753B2 (ja) |
CA (1) | CA2277277C (ja) |
CZ (1) | CZ297098B6 (ja) |
DE (2) | DE19800523C2 (ja) |
DK (1) | DK0961611T3 (ja) |
ES (1) | ES2175676T3 (ja) |
HU (1) | HU224224B1 (ja) |
ID (1) | ID22698A (ja) |
IL (1) | IL130872A (ja) |
NO (1) | NO993383D0 (ja) |
NZ (1) | NZ336691A (ja) |
PL (1) | PL193282B1 (ja) |
PT (1) | PT961611E (ja) |
SK (1) | SK93999A3 (ja) |
WO (1) | WO1998031341A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19822278A1 (de) * | 1998-05-18 | 1999-12-02 | Lohmann Therapie Syst Lts | Vorrichtung zur kontrollierten Freisetzung von Wirkstoff im Gastrointestinaltrakt mit verzögerter Pyloruspassage |
DE19837073A1 (de) * | 1998-08-17 | 2000-03-23 | Lohmann Therapie Syst Lts | Folienförmige Wirkstoffträger |
DE19849848A1 (de) * | 1998-10-29 | 2000-05-04 | Lohmann Therapie Syst Lts | Oral applizierbare, mit Flüssigkeit spontan zerfallende therapeutische Darreichungsform und Verfahren zu ihrer Herstellung |
DE19850309A1 (de) * | 1998-10-30 | 2000-05-04 | Lohmann Therapie Syst Lts | Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer |
DE19920854A1 (de) * | 1999-05-06 | 2000-11-16 | Lohmann Therapie Syst Lts | Verfahren und Vorrichtung zum Herstellen eines gastroretentiven flachen Schlauchbeutels mit Längsnaht |
DE19920838A1 (de) * | 1999-05-06 | 2000-11-16 | Lohmann Therapie Syst Lts | Gastroretentives System mit Kapillaren |
DE19920855A1 (de) * | 1999-05-06 | 2000-11-16 | Lohmann Therapie Syst Lts | Magenvolumenreduzierende Darreichungsform |
DE19920837A1 (de) * | 1999-05-06 | 2000-11-16 | Lohmann Therapie Syst Lts | Gastroretentives System für verlängerte Verweilzeit im Magen bzw. im Gastrointestinaltrakt |
DE19920833A1 (de) * | 1999-05-06 | 2000-11-16 | Lohmann Therapie Syst Lts | Gastroretentives System mit quellbaren Polymeren |
AU767812B2 (en) | 2000-02-04 | 2003-11-27 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
GB0102725D0 (en) * | 2001-02-02 | 2001-03-21 | Stowic Resources Ltd | Medical delivery system |
EP1245227A1 (en) | 2001-03-31 | 2002-10-02 | Jagotec Ag | A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same |
WO2003051329A1 (de) * | 2001-12-17 | 2003-06-26 | Beisel Guenther | Mittel zur oralen einnahme und verfahren zu dessen herstellung |
US6869333B2 (en) * | 2002-09-11 | 2005-03-22 | National Optronics, Inc. | Lens blank alignment and blocking device and method |
WO2004032906A1 (en) * | 2002-10-11 | 2004-04-22 | Depomed Development, Ltd. | Gastro-retentive levodopa delivery form |
TW200533391A (en) | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
JP2008508225A (ja) * | 2004-07-30 | 2008-03-21 | メリオン リサーチ ザ セカンド リミティド | 胃内保持装置の改良された自動製造方法及び機械 |
US8852083B2 (en) * | 2005-02-04 | 2014-10-07 | Uti Limited Partnership | Self-stabilized encapsulated imaging system |
KR100822519B1 (ko) * | 2005-02-15 | 2008-04-16 | 주식회사종근당 | 위장 내에서 제어방출되는 단일 매트릭스 정제 |
CA2675230A1 (en) * | 2006-01-10 | 2008-07-26 | Pipex, Inc. | Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases |
US9579227B2 (en) * | 2006-03-29 | 2017-02-28 | Eat Little Inc. | Ingestible implement for weight control |
WO2007109904A1 (en) * | 2006-03-29 | 2007-10-04 | Electronic Dietary Foods Inc. | Ingestible implement for weight control |
US8795721B2 (en) * | 2006-12-18 | 2014-08-05 | Eatlittle Inc. | Device for delivery of a substance |
US20080286343A1 (en) * | 2007-05-16 | 2008-11-20 | Dzenana Cengic | Solid form |
EP2490677A2 (en) * | 2009-10-19 | 2012-08-29 | Intec Pharma Ltd. | Novel gastroretentive dosage forms of poorly soluble drugs |
US20140343452A1 (en) * | 2011-12-21 | 2014-11-20 | Eatlittle Inc. | Pseudobezoar-Based Intraluminal Gastrointestinal Cleansing and Biospy |
US11529310B2 (en) | 2020-12-08 | 2022-12-20 | Ruminant Biotech Corp Limited | Devices and methods for delivery of substances to animals |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4207890A (en) | 1977-01-04 | 1980-06-17 | Mcneilab, Inc. | Drug-dispensing device and method |
DE3400106A1 (de) | 1984-01-04 | 1985-07-11 | Klaus-Dieter Dr. 3550 Marburg Bremecker | Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung |
AU6541786A (en) * | 1985-10-09 | 1987-05-05 | Desitin Arzneimittel Gmbh | Process for producing an administration or dosage form of drugs, reagents or other active ingredients |
IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
DE3812799A1 (de) * | 1988-04-16 | 1989-10-26 | Sanol Arznei Schwarz Gmbh | Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung |
EP0408496A3 (en) * | 1989-07-12 | 1992-07-01 | Ciba-Geigy Ag | Solid dosage form for pharmaceutical substances |
SK279964B6 (sk) * | 1991-12-27 | 1999-06-11 | Merck & Co. | Dávkovacia forma na riadené uvoľňovanie liečiva a |
GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
DE4406424A1 (de) * | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
-
1998
- 1998-01-09 AU AU62922/98A patent/AU727753B2/en not_active Ceased
- 1998-01-09 HU HU0000943A patent/HU224224B1/hu not_active IP Right Cessation
- 1998-01-09 PL PL334834A patent/PL193282B1/pl not_active IP Right Cessation
- 1998-01-09 SK SK939-99A patent/SK93999A3/sk unknown
- 1998-01-09 JP JP53131998A patent/JP3825811B2/ja not_active Expired - Fee Related
- 1998-01-09 AT AT98906865T patent/ATE214916T1/de active
- 1998-01-09 DE DE19800523A patent/DE19800523C2/de not_active Expired - Fee Related
- 1998-01-09 ES ES98906865T patent/ES2175676T3/es not_active Expired - Lifetime
- 1998-01-09 NZ NZ336691A patent/NZ336691A/xx not_active IP Right Cessation
- 1998-01-09 DE DE59803511T patent/DE59803511D1/de not_active Expired - Lifetime
- 1998-01-09 CZ CZ0249599A patent/CZ297098B6/cs not_active IP Right Cessation
- 1998-01-09 IL IL13087298A patent/IL130872A/en not_active IP Right Cessation
- 1998-01-09 ID IDW990690A patent/ID22698A/id unknown
- 1998-01-09 EP EP98906865A patent/EP0961611B1/de not_active Expired - Lifetime
- 1998-01-09 DK DK98906865T patent/DK0961611T3/da active
- 1998-01-09 KR KR10-1999-7006405A patent/KR100503266B1/ko not_active IP Right Cessation
- 1998-01-09 CA CA002277277A patent/CA2277277C/en not_active Expired - Fee Related
- 1998-01-09 US US09/341,492 patent/US6290989B1/en not_active Expired - Fee Related
- 1998-01-09 WO PCT/EP1998/000099 patent/WO1998031341A1/de active IP Right Grant
- 1998-01-09 PT PT98906865T patent/PT961611E/pt unknown
-
1999
- 1999-07-08 NO NO993383A patent/NO993383D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU727753B2 (en) | 2000-12-21 |
CA2277277C (en) | 2005-03-08 |
CA2277277A1 (en) | 1998-07-23 |
NO993383L (no) | 1999-07-08 |
IL130872A (en) | 2004-02-19 |
KR100503266B1 (ko) | 2005-07-25 |
WO1998031341A1 (de) | 1998-07-23 |
PL334834A1 (en) | 2000-03-27 |
ATE214916T1 (de) | 2002-04-15 |
NZ336691A (en) | 2000-05-26 |
DK0961611T3 (da) | 2002-07-15 |
AU6292298A (en) | 1998-08-07 |
HUP0000943A2 (hu) | 2000-10-28 |
SK93999A3 (en) | 2000-01-18 |
PT961611E (pt) | 2002-09-30 |
NO993383D0 (no) | 1999-07-08 |
HU224224B1 (hu) | 2005-06-28 |
DE59803511D1 (de) | 2002-05-02 |
CZ297098B6 (cs) | 2006-09-13 |
EP0961611B1 (de) | 2002-03-27 |
ES2175676T3 (es) | 2002-11-16 |
DE19800523C2 (de) | 1999-01-21 |
IL130872A0 (en) | 2001-01-28 |
ID22698A (id) | 1999-12-09 |
CZ249599A3 (cs) | 2000-01-12 |
DE19800523A1 (de) | 1998-07-30 |
HUP0000943A3 (en) | 2000-11-28 |
JP3825811B2 (ja) | 2006-09-27 |
EP0961611A2 (de) | 1999-12-08 |
PL193282B1 (pl) | 2007-01-31 |
US6290989B1 (en) | 2001-09-18 |
KR20000070179A (ko) | 2000-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001508068A (ja) | 胃腸系での活性物質の制御放出を用いた膨張性胃内貯留治療システム | |
EP1620075B1 (en) | Highly plastic granules for making fast melting tablets | |
ES2324205T3 (es) | Medicamento a base de microcapsulas de anti-hiperglucemiante de liberacion prolongada y su procedimiento de preparacion. | |
Yadav et al. | Fast dissolving tablets recent advantages: A review | |
JP2001524956A (ja) | 迅速溶解性の頑丈な投与形態物 | |
JP2009539894A (ja) | 組合せ抗高血圧症薬ウェーハ | |
CA2286079A1 (en) | Cefadroxil monohydrate tablet formulation | |
Rajak et al. | Gastroretentive floating drug delivery system: an approach in gastroretentive drug delivery | |
Patil et al. | Floating microspheres: A promising approach for gastric retention | |
Singh et al. | Dosage forms: non-parenterals | |
JP2016531161A (ja) | 低ナトリウム発泡性医薬製剤 | |
KR100612520B1 (ko) | 신속용융 정제를 제조하기 위한 고소성 과립 | |
CA3220327A1 (en) | Method of production of the composition of cyclooxygenase-2 (cox-2) inhibitors | |
JPH0147441B2 (ja) | ||
MXPA99006536A (es) | Sistema terapeutico gastro-retentivo, expandible con sustancia activa de liberacion controlada en el tracto gastro-intestinal | |
Seomoon et al. | MAKING FAST MELTING TABLETS | |
Gangurde et al. | Gastroretentive Dosage Forms: An Overview | |
WO2003075918A1 (fr) | Comprime contenant du chlorhydrate de pilsicainide (voie humide) | |
Katori | Colloid and Surface Phenomena |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040727 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060703 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090707 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100707 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110707 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110707 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120707 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |